Some of the world’s premier researchers in cannabis and cannabinoid science are leading Research and Development Programs that support Emerald Health Sciences’ investments. Through a Collaborative Research Agreement with the University of Eastern Piedmont (UPO) in Italy, EHS’s Drug Discovery program benefits from the expertise of Dr. Giovanni Appendino. He has been studying cannabis and cannabinoids for more than 15 years and is regarded by the global scientific community as one of the worlds thought leaders in cannabinoid research for therapeutic applications.
Pioneers in the development of new cannabinoid derivatives
Emerald Health Sciences’ Drug Development programs are carried out in partnership with VivaCell Biotechnology, a worldwide pioneer in the discovery and development of new cannabinoid and cannibigerol derivatives for the treatment of inflammatory and neurodegenerative diseases.